How to Monitor Response During Concurrent ERP and PE Treatment
How should clinicians track progress and decide whether to continue or extend concurrent ERP and prolonged exposure for comorbid obsessive-compulsive disorder and posttraumatic stress disorder?
Clinicians treating comorbid obsessive-compulsive disorder and posttraumatic stress disorder need realistic benchmarks for when improvement should appear and when a longer course may be necessary. This guide translates the article's symptom-monitoring and response benchmarks into a practical follow-up workflow.
-
Track both disorders with disorder-specific scales
Follow PTSD symptoms with the PCL-5 and OCD symptoms with the DOCS throughout treatment. The article analyzed change from baseline to session 20, session 40, and final session, highlighting the importance of monitoring both conditions rather than assuming improvement in one reflects the other.
-
Use explicit response thresholds
Define PTSD response as at least a 10-point reduction on the PCL-5. Define OCD response as at least a 25% DOCS reduction for partial response or at least a 35% DOCS reduction for full response; define combined response as meeting both the at least 10-point PCL-5 reduction and at least 35% DOCS reduction at the same time.
-
Reassess progress by about session 20
Use session 20 as an early benchmark for meaningful improvement. In the study, mean PCL-5 scores fell from 43.5 to 35.0 and mean DOCS scores fell from 35.2 to 24.5 by session 20, and among eventual responders, 81.9% of OCD responders, 68.0% of PTSD responders, and 55.0% of dual responders first responded within 20 sessions.
-
Expect OCD improvement to precede PTSD in many responders
Set expectations that OCD response may emerge before PTSD response during concurrent care. Among patients who achieved and maintained response through the final session, median time to first response was 11 sessions for OCD, 15 sessions for PTSD, and 20 sessions for dual response.
-
Review status again at session 40 without assuming treatment is complete
Use session 40 as an extended-treatment checkpoint rather than a hard stopping point. At session 40, 36.8% achieved PTSD response, 58.4% achieved at least 25% DOCS response, 42.9% achieved at least 35% DOCS response, and 17.1% achieved combined response among those with available data.
-
Continue treatment flexibly when both disorders remain active
Do not assume lack of dual response by session 40 means treatment has failed. The article found that 13.5% of patients who eventually achieved and maintained dual response first did so only after more than 40 sessions, and patients who continued beyond session 40 showed substantial additional improvement by their final session.
Clinical Considerations
- Time-to-response findings apply specifically to patients who achieved and maintained response through their final session, not to all treated patients.
- Only 42.5% of the sample reached session 40, and earlier treatment termination may have reflected completion, discontinuation, shifting focus, or external factors.
- Outcome measurement relied on self-report scales, and the authors noted that patients may have difficulty distinguishing OCD from PTSD symptoms.
- Routine postdischarge follow-up was not collected, so the article does not establish long-term maintenance of response.
Bottom Line
Monitor both PCL-5 and DOCS during concurrent ERP and PE, look for meaningful change by session 20, and remain willing to extend treatment beyond 40 sessions when dual OCD and PTSD response has not yet fully emerged.
